Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Long-Acting Insulin Analogs and the Risk of Diabetic Ketoacidosis in Children and Adolescents With Type 1 Diabetes

A prospective study of 10,682 patients from 271 institutions

  1. Beate Karges, MD1,
  2. Thomas Kapellen, MD2,
  3. Andreas Neu, MD3,
  4. Sabine E. Hofer, MD4,
  5. Tilman Rohrer, MD5,
  6. Joachim Rosenbauer, MD6,
  7. Johannes Wolf, MD7,
  8. Reinhard W. Holl, MD8 and
  9. for the Diabetes Prospective Documentation (DPV) Initiative and the German Federal Ministry for Education and Research (BMBF) Competence Network of Diabetes Mellitus*
  1. 1Division of Endocrinology and Diabetes, RWTH Aachen University, Aachen, Germany;
  2. 2Department of Pediatrics, University of Leipzig, Leipzig, Germany;
  3. 3University Children's Hospital Tübingen, Tübingen, Germany;
  4. 4Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria;
  5. 5Department of Pediatrics, University of Homburg-Saar, Homburg-Saar, Germany;
  6. 6Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Center at University of Düsseldorf, Düsseldorf, Germany;
  7. 7Children's Hospital Paderborn, Paderborn, Germany;
  8. 8Department of Epidemiology, University of Ulm, Ulm, Germany.
  1. Corresponding author: Beate Karges, bkarges{at}ukaachen.de.
Diabetes Care 2010 May; 33(5): 1031-1033. https://doi.org/10.2337/dc09-2249
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To investigate if long-acting insulin analogs decrease the risk of diabetic ketoacidosis (DKA) in young individuals with type 1 diabetes.

RESEARCH DESIGN AND METHODS Of 48,110 type 1 diabetic patients prospectively studied between 2001 and 2008, the incidence of DKA requiring hospitalization was analyzed in 10,682 individuals aged ≤20 years with a diabetes duration of ≥2 years.

RESULTS The overall rate of DKA was 5.1 (SE ± 0.2)/100 patient-years. Patients using insulin glargine or detemir (n = 5,317) had a higher DKA incidence than individuals using NPH insulin (n = 5,365, 6.6 ± 0.4 vs. 3.6 ± 0.3, P < 0.001). The risk for DKA remained significantly different after adjustment for age at diabetes onset, diabetes duration, A1C, insulin dose, sex, and migration background (P = 0.015, odds ratio 1.357 [1.062–1.734]).

CONCLUSIONS Despite their long-acting pharmacokinetics, the use of insulin glargine or detemir is not associated with a lower incidence of DKA compared with NPH insulin.

Lipolysis and ketogenesis leading to diabetic ketoacidosis (DKA) may be suppressed by the continuous provision of small doses of insulin (1,2). DKA is frequently caused by omission of insulin injections, observed in 28–65% of young patients with type 1 diabetes (3,4). In young children, the use of insulin glargine and detemir was associated with a trend to less DKA episodes compared with NPH/zinc insulin (5), potentially related to the prolonged action of these insulin analogs (6–8). We hypothesized that long-acting insulin analogs may confer greater protection from DKA in young patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS

Based on the Diabetes Prospective Documentation (DPV) Initiative (9), a study was performed to evaluate the incidence of DKA in patients with type 1 diabetes using either NPH insulin or long-acting basal insulin analogs. A total of 48,110 patients with type 1 diabetes were consecutively registered between 2001 and 2008 at 271 diabetes centers in Germany and Austria, with an estimated nationwide capture rate of ≥80%.

Subjects aged ≤20 years with diabetes duration ≥2 years using three or more insulin injections daily without change of type of long-acting insulin during the last 18 months were included into the study. Insulin therapy was not modified for study purposes. DKA was defined as venous blood pH <7.3 and the requirement of hospital treatment. DKA incidence during the recent 12 treatment months was assessed. Locally measured A1C was standardized to the Diabetes Control and Complications Trial (DCCT) reference range of 4.05–6.05% using the multiple of the mean method.

Statistical analyses were performed using SAS software (SAS version 9.1; SAS Institute, Cary, NC). Nonparametric (Kruskal-Wallis) or χ2 statistics were used for comparison among groups followed by the Holm adjustment (Bonferroni step-down) for multiple comparisons. P values <0.05 were considered statistically significant. Odds ratios (OR) derived from multiple logistic regression analysis were listed as point estimates and 95% Wald CI.

RESULTS

Of 48,110 eligible patients with type 1 diabetes, 26,639 individuals were aged ≤20 years with a diabetes duration of ≥2 years. Subjects with continuous subcutaneous insulin injections (n = 4,553), change in basal insulin during the last 18 months (n = 9,334), less than three injections per day or no documented basal insulin (n = 1,053), missing documentation of insulin therapy (n = 792), or the use of zinc intermediate-acting insulin (n = 225) were excluded. In effect, 10,682 individuals (mean age 14.2 ± 4.1 years, median 15.3) were included in the analysis.

Clinical characteristics of patients using long-acting basal insulin analogs (n = 5,317) or NPH insulin (n = 5,365) are summarized in Table 1. The overall number of DKA events in the entire cohort was 549 during the recent treatment year, corresponding to a DKA incidence of 5.14 ± 0.22 (SE/100 patient-years).

View this table:
  • View inline
  • View popup
Table 1

Clinical characteristics and incidence of DKA in 10,682 patients with type 1 diabetes from 271 centers

Patients using long-acting insulin analogs had higher DKA risk than patients with NPH insulin (Table 1). Multiple logistic regression analysis with adjustment for A1C, diabetes duration, age at diabetes onset, sex, migration background, insulin therapy (dose of short-acting insulin analogs, daily insulin dose, prandial/basal ratio), and treatment year confirmed higher DKA risk in the long-acting insulin analog group compared with the NPH insulin group (P = 0.015, OR 1.357 [95% CI 1.062–1.734]).

Independent variables associated with higher DKA risk were higher insulin dose (P < 0.001) and higher A1C level (P < 0.001). However, dose of short-acting insulin analogs, insulin ratio (prandial/basal), age at diabetes onset, diabetes duration, sex, migration background, and treatment year were not significantly associated with DKA risk.

In patients with poor metabolic control (A1C ≥9.0%, n = 2,652), DKA incidence was 13.7 ± 0.72/100 patient-years. In these patients, 63% used basal insulin analogs. Treatment with long-acting insulin analogs was associated with higher DKA risk compared with NPH insulin (P = 0.003, OR 1.639 [95% CI 1.180–2.277]) in this subgroup of patients.

When DKA risk was separately analyzed for insulin glargine or detemir versus NPH, the association with higher DKA risk was confirmed for both long-acting insulin analogs (P = 0.035, OR 1.268 [95% CI 0.978–1.643] and 1.526 [1.092–2.133]). In patients with poor metabolic control, even higher DKA incidences associated with insulin glargine or detemir compared with NPH were found (P = 0.011, OR 1.470 [1.046–2.065] and 1.906 [1.226–2.963]).

CONCLUSIONS

The use of long-acting insulin analogs was not associated with a lower DKA incidence in our study population, representing ≥80% of pediatric patients with type 1 diabetes of ≥2 years' duration in Germany and Austria. In this cohort of 10,682 individuals, we found 5.14 DKA events/100 patient-years, similar to previous observations (10). Patients using long-acting insulin analogs had higher DKA incidence than individuals using NPH insulin. In a previous smaller study, a nonsignificant trend of less DKA episodes was described in children injecting long-acting insulin analogs (5), but mean patient age (6.5 years) and overall DKA risk were lower in that series, which may account for the differences to our findings.

Our results were derived from an observational nonrandomized prospective study. In the study population, patients injecting long-acting insulin analogs were older, had poorer metabolic control, and more frequently used short-acting insulins than those injecting NPH—all factors potentially increasing DKA risk. However, after adjusting for these factors, higher DKA risk in patients with long-acting insulin analogs persisted, suggesting that observed differences are indeed related to insulin therapy. A variety of additional factors may influence the risk of DKA in type 1 diabetic patients, including treatment adherence, socioeconomic status, infections, or residual β-cell function (3,10,11). In our population-based study, these variables could not be separately assessed. DKA is frequently caused by omission of particularly the long-acting component of a basal-bolus insulin regimen (10,11). Missing a once-daily injection of a long-acting insulin analog may potentially contribute to a greater DKA risk than missing one of two or three NPH injections.

In conclusion, despite their long-acting pharmacokinetic profile, the use of long-acting insulin analogs was not associated with a lower incidence of DKA compared with NPH insulin. The possibility of increased DKA risk in pediatric patients injecting insulin glargine or detemir warrants further attention.

Acknowledgments

This work was supported by the Competence Network for diabetes funded by the Federal Ministry of Education and Research (FKZ 01GI0859), Berlin, Germany; European Foundation for the Study of Diabetes; and the Excellence Center “Metabolism,” Baden-Württemberg. DPV software development was supported by Novo-Nordisk.

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • ↵*A list of participating DPV centers is available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc09-2249/DC1.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received December 10, 2009.
    • Accepted February 14, 2010.
  • © 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Wagner A,
    2. Risse A,
    3. Brill HL,
    4. Wienhausen-Wilke V,
    5. Rottmann M,
    6. Sondern K,
    7. Angelkort B
    : Therapy of severe diabetic ketoacidosis: zero-mortality under very-low-dose insulin application. Diabetes Care 1999; 22: 674– 677
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. DeFronzo R,
    2. Matsuda M,
    3. Barret E
    : Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2: 209– 238
    OpenUrl
  3. ↵
    1. Morris AD,
    2. Boyle DI,
    3. McMahon AD,
    4. Greene SA,
    5. MacDonald TM,
    6. Newton RW
    : Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997; 350: 1505– 1510
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Burdick J,
    2. Chase HP,
    3. Slover RH,
    4. Knievel K,
    5. Scrimgeour L,
    6. Maniatis A,
    7. Klingensmith GJ
    : Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004; 113: 221– 224
    OpenUrlCrossRef
  5. ↵
    1. Wagner VM,
    2. Rosenbauer J,
    3. Grabert M,
    4. Holl RW
    : the German Initiative on Quality Control in Pediatric Diabetology. Severe hypoglycemia, metabolic control, and diabetes management in young children with type 1 diabetes using insulin analogs: a follow-up report of a large multicenter database. Eur J Pediatr 2008; 167: 241– 242
    OpenUrlCrossRefPubMed
  6. ↵
    1. Porcellati F,
    2. Rossetti P,
    3. Busciantella NR,
    4. Marzotti S,
    5. Lucidi P,
    6. Luzio S,
    7. Owens DR,
    8. Bolli GB,
    9. Fanelli CG
    : Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes. Diabetes Care 2007; 30: 2447– 2452
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bangstad HJ,
    2. Danne T,
    3. Deeb LC,
    4. Jarosz-Chobot P,
    5. Urakami T,
    6. Hanas R
    : Insulin treatment. ISPAD Clinical Practice Consensus Guidelines 2006–2007. Pediatr Diabetes 2007; 8: 88– 102
    OpenUrlPubMedWeb of Science
  8. ↵
    1. Robertson KJ,
    2. Schoenle E,
    3. Gucev Z,
    4. Mordhorst L,
    5. Gall MA,
    6. Ludvigsson J
    : Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007; 24: 27– 34
    OpenUrlCrossRefPubMed
  9. ↵
    1. Schwab KO,
    2. Doerfer J,
    3. Hecker W,
    4. Grulich-Henn J,
    5. Wiemann D,
    6. Kordonouri O,
    7. Beyer P,
    8. Holl RW
    : the DPV Initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006; 29: 218– 225
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Wolfsdorf J,
    2. Craig ME,
    3. Daneman D,
    4. Dunger D,
    5. Edge J,
    6. Lee WRW,
    7. Rosenbloom A,
    8. Sperling MA,
    9. Hanas R
    : ISPAD Clinical Practice Consensus Guidelines 2006–2007. Diabetic ketoacidosis. Pediatr Diabetes 2007; 8: 28– 43
    OpenUrlPubMedWeb of Science
  11. ↵
    1. Rewers A,
    2. Chase HP,
    3. Mackenzie T,
    4. Walravens P,
    5. Roback M,
    6. Rewers M,
    7. Hamman RF,
    8. Klingensmith G
    : Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287: 2511– 2518
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 33 (5)

In this Issue

May 2010, 33(5)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-Acting Insulin Analogs and the Risk of Diabetic Ketoacidosis in Children and Adolescents With Type 1 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Long-Acting Insulin Analogs and the Risk of Diabetic Ketoacidosis in Children and Adolescents With Type 1 Diabetes
Beate Karges, Thomas Kapellen, Andreas Neu, Sabine E. Hofer, Tilman Rohrer, Joachim Rosenbauer, Johannes Wolf, Reinhard W. Holl, for the Diabetes Prospective Documentation (DPV) Initiative and the German Federal Ministry for Education and Research (BMBF) Competence Network of Diabetes Mellitus
Diabetes Care May 2010, 33 (5) 1031-1033; DOI: 10.2337/dc09-2249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Long-Acting Insulin Analogs and the Risk of Diabetic Ketoacidosis in Children and Adolescents With Type 1 Diabetes
Beate Karges, Thomas Kapellen, Andreas Neu, Sabine E. Hofer, Tilman Rohrer, Joachim Rosenbauer, Johannes Wolf, Reinhard W. Holl, for the Diabetes Prospective Documentation (DPV) Initiative and the German Federal Ministry for Education and Research (BMBF) Competence Network of Diabetes Mellitus
Diabetes Care May 2010, 33 (5) 1031-1033; DOI: 10.2337/dc09-2249
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Suicide Risk Assessment in Youth and Young Adults With Type 1 Diabetes
  • Plasma Lipidome and Prediction of Type 2 Diabetes in the Population-Based Malmö Diet and Cancer Cohort
  • Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Show more Original Research

Clinical Care/Education/Nutrition/Psychosocial Research

  • Changes in Consumption of Sugary Beverages and Artificially Sweetened Beverages and Subsequent Risk of Type 2 Diabetes: Results From Three Large Prospective U.S. Cohorts of Women and Men
  • Genetic Prediction of Serum 25-Hydroxyvitamin D, Calcium, and Parathyroid Hormone Levels in Relation to Development of Type 2 Diabetes: A Mendelian Randomization Study
  • One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System
Show more Clinical Care/Education/Nutrition/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.